Tellgen Corporation was established in 2003 at the Medicine Valley in Shanghai, also known as the Silicon Valley of China, which went public in 2017 in Shenzhen and grew to 1000 employees. The Tellgen Corporation focuses on tumor markers detection, provide total solution from screening to prognosis evaluation related products for customers. The methodology platform employed including immunofluorescence, chemiluminescence immunoassay and multiple fluorescent PCR, mass spectrometry, etc. Tellgen is one of the global strategic partners with Luminex Corp. Meanwhile, Tellgen is the first one to launch an automated high-throughput immunoassay system (TESMI) based on fluorescence flowcytometry technology. In 2019, we have introduced a total laboratory automation streamline: TESMI Connection Modules（TCM). Tellgen corporation will always adhere to the R & D philosophy of “internalizing technology knowledge globally & ploughing self-innovation locally”, TellgenCoporation strives to become an influential company in the field of international life science and contribute to public health.